Key result
Systemic nivolumab resolves malignant pericarditis and shrinks epicardial nodules in a metastatic esophageal cancer case.
Why the study?
Malignant pericarditis secondary to esophageal cancer can cause repetitive pericardial effusion and cardiac tamponade, occasionally posing a clinical challenge.
Case Report (n=1)
Systemic nivolumab monotherapy combined with pericardial drainage may be a promising option for managing malignant pericarditis in patients with metastatic esophageal cancer.
May support nivolumab for malignant pericarditis in esophageal cancer; hypothesis-generating from one case and requires prospective validation.
Esophageal cancer is a malignant disease with a poor prognosis and is one of the most common causes of cardiac metastasis. Malignant pericarditis may cause the repetitive accumulation of pericardial effusion, which can occasionally pose a clinical challenge. We herein report a case of malignant pericarditis in a patient with metastatic esophageal squamous cell carcinoma with cardiac tamponade, which was successfully managed with single pericardial drainage and systemic nivolumab monotherapy. This is the first case report to suggest that systemic therapy with nivolumab is a promising option for the management of malignant pericarditis.
No takes yet. Share an insight, caveat, or question.
Uneno et al. (2023) conducted a case report in Malignant pericarditis with metastatic esophageal squamous cell carcinoma (n=1). Nivolumab was evaluated on Reduction in pericardial effusion and epicardial nodule size. Systemic nivolumab monotherapy successfully managed malignant pericarditis and reduced epicardial nodule size in a patient with metastatic esophageal squamous cell carcinoma.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: